Clinical Trials Browser

INDUSTRY × immunotoxin HA22 × Clear all

NCT03501615 2020-06-29

MOXE

Approved for marketing

Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell

NCT01829711 2020-04-08

Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia

Phase 3 Completed

80 enrolled 32 charts 1 FDA

Other hematologic neoplasm

Leukemia, Hairy Cell

NCT00586924 2019-04-02

A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia

Phase 1 Completed

49 enrolled 40 charts

Other hematologic neoplasm

Leukemia, Hairy Cell

NCT01030536 2018-04-09

Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)

Phase 1/2 Completed

23 enrolled 26 charts

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00659425 2017-10-02

CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Phase 1 Completed

57 enrolled 34 charts

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00587457 2017-07-06

A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia

Phase 1 Terminated

11 enrolled 14 charts

LymphoidOther hematologic neoplasm

Cerebral Palsy, Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT00587015 2011-11-22

A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin's Lymphoma (NHL)

Phase 1 Terminated

Lymphoma